Sotera Health (NYSE:SHC) Releases FY 2021 Earnings Guidance

Sotera Health (NYSE:SHC) issued an update on its FY 2021 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.870-$0.880 for the period, compared to the Thomson Reuters consensus estimate of $0.890. The company issued revenue guidance of $920 million-$930 million, compared to the consensus revenue estimate of $932.86 million.

Several research analysts have recently weighed in on the company. Barclays boosted their target price on Sotera Health from $30.00 to $32.00 and gave the stock an overweight rating in a report on Friday, August 13th. Zacks Investment Research cut Sotera Health from a hold rating to a sell rating in a report on Saturday, November 20th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Buy and an average target price of $32.14.

NYSE SHC traded up $0.10 on Thursday, reaching $21.91. The stock had a trading volume of 657,454 shares, compared to its average volume of 987,015. The firm has a market capitalization of $6.20 billion and a price-to-earnings ratio of 182.60. The company has a quick ratio of 2.46, a current ratio of 2.52 and a debt-to-equity ratio of 3.39. Sotera Health has a 12-month low of $21.18 and a 12-month high of $30.38. The stock has a fifty day moving average price of $25.20 and a two-hundred day moving average price of $24.38.

Sotera Health (NYSE:SHC) last announced its earnings results on Wednesday, November 10th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $226.16 million for the quarter, compared to analyst estimates of $222.55 million. Sotera Health had a return on equity of 35.74% and a net margin of 4.10%. Sell-side analysts forecast that Sotera Health will post 0.85 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of SHC. UBS Group AG increased its position in shares of Sotera Health by 461.7% during the third quarter. UBS Group AG now owns 19,259 shares of the company’s stock worth $504,000 after acquiring an additional 15,830 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Sotera Health by 296.5% during the third quarter. Dimensional Fund Advisors LP now owns 41,298 shares of the company’s stock worth $1,080,000 after acquiring an additional 30,882 shares during the period. Bank of New York Mellon Corp increased its position in shares of Sotera Health by 22.0% during the third quarter. Bank of New York Mellon Corp now owns 352,968 shares of the company’s stock worth $9,230,000 after acquiring an additional 63,674 shares during the period. Finally, Morgan Stanley increased its position in shares of Sotera Health by 852.3% during the second quarter. Morgan Stanley now owns 481,151 shares of the company’s stock worth $11,659,000 after acquiring an additional 430,628 shares during the period. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

Featured Article: What is a stock split?

Earnings History and Estimates for Sotera Health (NYSE:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.